Gilead's John C. Martin - CEO Pay

Gilead CEO John C. MartinJohn C. Martin - Gilead

Total Compensation: $11M

Details: With the company raking in over $42 billion in revenue in 2007--a 40percent increase over 2006--Gilead was pretty happy with their chief going into 2008. So happy, in fact, that the company threw their salary budget caps out of the window and awarded CEO Martin a 10 percent raise. Overall, Martin's total compensation package was bumped up $200,000 in 2008, which included the 10 percent increase in his base salary to $1,155,000 and some padding in the "other compensation" category.

Martin received $107,131 last for matching contributions to his retirement plan as well as reimbursement for costs related to antitrust filings triggered by regulatory requirements after Martin's stock in the company reached a certain value last year. Gilead felt it only right to reimburse the chief since the company requires him to be a shareholder. Those fees included the Hart-Scott Rodino filing fees ($45,000), related legal fees ($10,406) and associated tax reimbursement ($46,725).

Gilead News: 
Parion gets $5M milestone from Gilead
FDA rejects Gilead's CF drug
Gilead doubles jobs, space to boost development
Gilead numbers ‘uninspiring'

Gilead's John C. Martin - CEO Pay
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.